Schedule 13D - Activist Investments
NASDAQ
LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. have disclosed a 10.6% beneficial ownership in AgomAb Therapeutics NV following an IPO and additional share purchases.
Capital raise
Schedule 13G - Passive Investments
NASDAQ
Redmile Group, LLC and Jeremy C. Green have filed a Schedule 13G reporting a 5.6% beneficial ownership stake in AgomAb Therapeutics NV.
NASDAQ
SCHEDULE: Agomab Therapeutics Stakeholder Filing
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 5.01% of Agomab Therapeutics NV's American Depositary Shares.
NASDAQ
Sanofi has reported beneficial ownership of 5.71% of AgomAb Therapeutics' common shares, totaling 2,783,096 shares.
NASDAQ
Investment firm Pontifax has filed a Schedule 13G reporting a 6.8% beneficial ownership stake in Agomab Therapeutics NV.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a 10.0% beneficial ownership stake in Agomab Therapeutics SA, totaling 4,873,680 common shares.